Zai Lab Limited Unsponsored ADR $ZLAB Shares Acquired by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. lifted its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 106.9% in the third quarter, Holdings Channel.com reports. The firm owned 293,966 shares of the company’s stock after buying an additional 151,883 shares during the period. Nan Fung Trinity HK Ltd.’s holdings in Zai Lab were worth $7,743,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Zai Lab during the 3rd quarter valued at $62,000. Nykredit A S bought a new stake in Zai Lab in the second quarter worth $79,000. China Universal Asset Management Co. Ltd. purchased a new position in Zai Lab during the third quarter worth $211,000. WealthPlan Investment Management LLC purchased a new position in Zai Lab during the third quarter worth $969,000. Finally, Headlands Technologies LLC boosted its stake in Zai Lab by 142.0% during the second quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock worth $1,292,000 after buying an additional 39,901 shares during the period. Institutional investors own 41.65% of the company’s stock.

Zai Lab Stock Down 1.4%

ZLAB opened at $26.04 on Friday. The stock’s 50 day moving average price is $24.66 and its 200-day moving average price is $21.22. Zai Lab Limited Unsponsored ADR has a one year low of $15.96 and a one year high of $29.02.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. Zai Lab had a negative return on equity of 31.15% and a negative net margin of 44.91%. The firm had revenue of $108.21 million during the quarter, compared to analyst estimates of $107.90 million. Equities analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ZLAB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a research report on Tuesday, October 27th. Citigroup raised their target price on shares of Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Tuesday, October 6th. Finally, Wall Street Zen upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.25.

Zai Lab Company Profile

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.